Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery

Thrombosis and Haemostasis

Volumn 105, Issue 6, 2011, Pages 1072-1079

  Windyga, Jerzy ^a   von Depka Prondzinski, Mario ^b  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Werlhof Institut   (Germany)

Author keywords

Factor VIII; Surgery; Von Willebrand disease; Von Willebrand factor; Wilate

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WILATE;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOSTASIS; HUMAN; HUMAN PARVOVIRUS B19; INFECTION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MINOR SURGERY; MULTICENTER STUDY; OPEN STUDY; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; URTICARIA; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; CHILD; DRUG COMBINATIONS; DRUG EVALUATION; EUROPE; FACTOR VIII; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; TREATMENT OUTCOME; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 79958088726     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-10-0631     Document Type: Article

References (22)

1. Castaman G, Federici AB, Rodeghiero F, et al. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
2. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
3. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 (Suppl 1): S3-S10.
4. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16 (Suppl 1): S17-S21.
5. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
6. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621-625.
7. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118 (Suppl 1): S9-S11.
8. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-1455.
9. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34: 281-288.
10. Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease ddefficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-130.
11. Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-230.
12. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-694.
13. Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
14. Lethagen S, Kyrle PA, Castaman G, et al. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-1430.
15. Rivard GE, Aledort L. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008; 14: 271-275.
16. Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, et al. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate. Haemophilia 2008; 14: 963-967.
17. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
18. Kraaijenhagen RA, Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
19. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
20. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII: C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
21. Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-456.
22. Pock K, Stadler M, Gruber G, et al. Product features of novel generation VWF/ FVIII concentrate in a comparison with first generation products. J Thromb Haemost 2007; 5: Abstract P-W-183.